Stock Forecast

  Imago BioSciences, Inc. ( IMGO) Stock. Should you Buy or Sell?    $ 16.91

0.14 (0.82 %)



Imago BioSciences, Inc. Analysis

Updated on 10-09-2022
Symbol IMGO
Price $16.91
Beta 0.000
Volume Avg. $150.87 thousand
Market Cap $570.57 M
52 Week Range $11.56 - $30.21


Imago BioSciences, Inc. opened the day at $16.91 which is +'0.82 % on yesterday's close. Imago BioSciences, Inc. has a 52 week high of $30.21 and 52 week low of $11.56, which is a difference of $18.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $570.57 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Imago BioSciences, Inc. for $570.57 M, it would take 15 years to get your money back. Imago BioSciences, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Imago BioSciences, Inc. Stock Forecast - Is Imago BioSciences, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -10.091
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Imago BioSciences, Inc.


Price Book Value Ratio 3.045 Price To Book Ratio 3.045
Price To Sales Ratio 0.000 Price Earnings Ratio -10.091


How liquid is Imago BioSciences, Inc.


Current Ratio 21.951
Quick Ratio 21.658


Debt


Debt Ratio 0.045 Debt Equity Ratio 0.047
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Imago BioSciences, Inc.


Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.

Date : 06/09/2022

Imago BioSciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in three upcoming investor conferences.

Date : 16/05/2022

Why Earnings Season Could Be Great for Imago BioSciences (IMGO)

Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Date : 28/02/2022

Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021, at 10:40 a.m. ET.

Date : 11/11/2021

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

Date : 30/07/2021





About Imago BioSciences, Inc.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.imagobio.com

Exchange : NASDAQ Global Select

Description :

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.


My Newsletter

Sign Up For Updates & Newsletters